keyword
MENU ▼
Read by QxMD icon Read
search

anti-IgE

keyword
https://www.readbyqxmd.com/read/29150253/anti-ige-or-anti-il5-that-is-the-question
#1
REVIEW
Elliot Israel, Reynold A Panettieri
No abstract text is available yet for this article.
November 14, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29124807/combining-anti-ige-with-oral-immunotherapy
#2
EDITORIAL
Valérie Trendelenburg, Kirsten Beyer
No abstract text is available yet for this article.
November 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29106996/chronic-rhinosinusitis-endotypes-biomarkers-and-treatment-response
#3
Jose Gurrola, Larry Borish
It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of different diseases with distinct clinical presentations and pathogenic mechanisms. Defining the distinct phenotypes and endotypes of CRS impacts prognosis and most importantly is necessary as the basis for making therapeutic decisions. The need for individualized defining of pathogenic mechanisms prior to initiating therapy extends to virtually all therapeutic considerations. This is clearly crucial with antibiotics where, barring an influence from their off-target anti-inflammatory pharmacological effects, an understanding of the role of individual biome predicts likelihood of therapeutic benefit...
October 26, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29102514/efficacy-and-safety-of-omalizumab-for-the-treatment-of-refractory-chronic-spontaneous-urticaria-in-japanese-patients-subgroup-analysis-of-the-phase-3-polaris-study
#4
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil
BACKGROUND: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double-blind, placebo-controlled trial in East Asian patients. However, data in Japanese patients, who have specific baseline characteristics (e.g., low angioedema incidence, different background medications) that may impact clinical outcomes, are lacking...
November 1, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29096848/immunoadsorption-for-treatment-of-severe-atopic-dermatitis
#5
Joanna Wegner, Julia Weinmann-Menke, Esther von Stebut
Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Atopy is common in patients with AD and many patients have high levels of Immunoglobulin E (IgE), some of which recognizes exogenous or auto/self-allergens...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29083477/intranasal-administration-of-allergen-increases-specific-ige-whereas-intranasal-omalizumab-does-not-increase-serum-ige-levels-a-pilot-study
#6
Julia Eckl-Dorna, Renate Fröschl, Christian Lupinek, Renata Kiss, Pia Gattinger, Katharina Marth, Raffaela Campana, Katharina Blatt, Peter Valent, Regina Selb, Andrea Mayer, Katharina Gangl, Irene Steiner, Jutta Gamper, Thomas Perkmann, Petra Zieglmayer, Philippe Gevaert, Rudolf Valenta, Verena Niederberger
BACKGROUND: Administration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases of IgE antibody levels. OBJECTIVE: To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen-specific IgE in patients with birch pollen allergy. METHODS: Based on the fact that intranasal allergen application induces rises of systemic allergen-specific IgE we performed a double-blind placebo-controlled pilot trial in which birch pollen allergic subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1...
October 30, 2017: Allergy
https://www.readbyqxmd.com/read/29072882/rita-the-italian-severe-uncontrolled-asthma-registry
#7
Sara Maio, Sandra Baldacci, Megon Bresciani, Marzia Simoni, Manuela Latorre, Nicola Murgia, Fabrizio Spinozzi, Mariachiara Braschi, Leonardo Antonicelli, Barbara Brunetto, Patrizia Iacovacci, Paolo Roazzi, Carlo Pini, Mario Pata, Lidia La Grasta, Pierluigi Paggiaro, Giovanni Viegi
BACKGROUND: The Italian severe/uncontrolled asthma (SUA) web-based registry encompasses demographic, clinical, functional, inflammatory data; it aims to raise SUA awareness, identifying specific phenotypes and promoting optimal care. METHODS: 493 adult patients from 27 Italian centres (recruited in 2011-2014) were analyzed. RESULTS: Mean age was 53.8yrs. SUA patients were more frequently female (60.6%), with allergic asthma (83.1%). About 30% showed late onset of asthma diagnosis/symptoms (>40yrs); the mean age for asthma symptoms onset was 30...
October 26, 2017: Allergy
https://www.readbyqxmd.com/read/29036018/precision-medicine-in-asthma-linking-phenotypes-to-targeted-treatments
#8
Kian F Chung
PURPOSE OF REVIEW: Asthma is a heterogeneous disease consisting of different phenotypes that are driven by different mechanistic pathways. The purpose of this review is to emphasize the important role of precision medicine in asthma management. RECENT FINDINGS: Despite asthma heterogeneity, the approach to management has been on the basis of disease severity, with the most severe patients reserved for the maximum treatments with corticosteroids and bronchodilators...
October 13, 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/29027379/impact-of-omalizumab-in-children-from-a-middle-income-country-with-severe-therapy-resistant-asthma-a-real-life-study
#9
Paulo M Pitrez, Rodrigo G de Souza, Cristian Roncada, Joao P Heinzmann-Filho, Giovana Santos, Leonardo A Pinto, Marcus H Jones, Renato T Stein
BACKGROUND: Severe asthma in children is a global health problem. Severe therapy-resistant asthma (STRA) in children is a major clinical challenge due to persistent symptoms despite high doses of corticosteroids and results in high public health costs. Omalizumab (anti-IgE monoclonal antibody) has been described as an effective add-on therapy in these patients. The characteristics of children with STRA from low- and middle-income countries have scarcely been reported, and no real-life study has been published on the effects of omalizumab in this group of patients...
November 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28983485/anti-ige-treatment-for-disorders-other-than-asthma
#10
REVIEW
Jeffrey Stokes
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28968274/critical-appraisal-of-the-unmet-needs-in-the-treatment-of-chronic-spontaneous-urticaria-with-omalizumab-an-italian-perspective
#11
Riccardo Asero, Giorgio W Canonica, Antonio Cristaudo, Maria T Fierro, Giampiero Girolomoni, Angelo V Marzano, Eustachio Nettis, Patrizia Pepe, Paolo Pigatto, Oliviero Rossi
PURPOSE OF REVIEW: The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. RECENT FINDINGS: Although modern second-generation H1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients...
December 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28965921/therapeutic-approaches-of-asthma-and-copd-overlap
#12
REVIEW
Mitsuko Kondo, Jun Tamaoki
Asthma and COPD overlap (ACO) is an important clinical phenotype, due to the low-health-related quality of life (QOL), rapid decline in lung function, frequent exacerbation, and high economic burden. However, no large-scaled therapeutic trials of ACO have been conducted. At present, ACO is treated according to asthma/COPD guidelines. The goals of ACO treatment are to relieve symptoms and improve QOL and lung functions. Treatment must also prevent disease progression, airway remodeling, exacerbation, complications, and comorbidities...
September 28, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28947015/response-to-omalizumab-in-patients-with-severe-allergic-asthma-a-real-life-study
#13
Louise Zierau, Emil Schwarz Walsted, Simon Francis Thomsen, Vibeke Backer
INTRODUCTION: Omalizumab is a humanized monoclonal anti-IgE antibody, which is widely used for patients with severe uncontrolled asthma. Treatment with omalizumab is known to decrease the number of exacerbations and GETE score (Global Evaluation of Treatment Effectiveness) - but little is known about which patients benefit the most. Moreover, the time to discontinuation of the treatment with omalizumab has yet to be investigated. In this real-life study on a Danish population we explore these important issues...
October 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28918644/anti-ige-and-anti-il5-biologic-therapy-in-the-treatment-of-nasal-polyposis-a-systematic-review-and-meta-analysis
#14
REVIEW
Alexander Rivero, Jonathan Liang
OBJECTIVE: To determine the role of biologic therapy on sinonasal symptoms and objective outcomes in chronic rhinosinusitis with nasal polyposis (CRSwNP). METHODS: PubMed, OVID MEDLINE, and Cochrane Central were reviewed from 2000 to 2015. Inclusion criteria included English-language studies containing original data on biologic therapy in CRSwNP patients with reported outcome measures. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools...
November 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28916187/mast-cell-exosomes-can-suppress-allergic-reactions-by-binding-to-ige
#15
Guogang Xie, Haiwei Yang, Xia Peng, Lihui Lin, Juan Wang, Kun Lin, Zelin Cui, Jia Li, Hui Xiao, Yuting Liang, Li Li
Neutralizing free IgE would appear to be an important strategy for the treatment of allergic diseases. This article explores a novel anti-IgE agent.
September 12, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28910970/antibody-therapy-for-the-management-of-severe-asthma-with-eosinophilic-inflammation
#16
Ken Ohta, Hiroyuki Nagase, Maho Suzukawa, Shin Ohta
One of the characteristic features of asthma is chronic airway inflammation typically with eosinophil infiltration. Most asthmatics can be treated successfully with conventional treatment appropriate for their severity, but in some severe cases, asthma cannot be well controlled even with thorough treatment and this condition is known as 'refractory asthma'. To overcome severe refractory asthma, a new therapeutic strategy with biologics has been developed based on the knowledge of molecular mechanisms of airway inflammation in asthma, induced by the condition of high Th2-type responses and activation of eosinophils as well as allergic reactions...
July 1, 2017: International Immunology
https://www.readbyqxmd.com/read/28890861/idiopathic-anaphylaxis
#17
REVIEW
Bright I Nwaru, Sangeeta Dhami, Aziz Sheikh
Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests...
2017: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28888244/new-and-anticipated-therapies-for-severe-asthma
#18
Stephen P Peters, William W Busse
Asthma is frequently undertreated, resulting in a relatively high prevalence of patients with uncontrolled disease, characterized by the presence of symptoms and risk of adverse outcomes. Patients with uncontrolled asthma have a higher risk of morbidity and mortality, underscoring the importance of identifying uncontrolled disease and modifying management plans to improve control. Several assessment tools exist to evaluate control with various cutoff points and measures, but these tools do not reliably correlate with physiological measures and should be considered a supplement to physiological tests...
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28846472/the-current-state-of-food-allergy-therapeutics
#19
Meng Chen, Michael Land
The prevalence of IgE mediated food allergy is an increasing public health concern. The current standard of treatment is strict avoidance of the offending food(s). There are no FDA approved treatments for food allergy. This review will provide an overview of strategies currently under investigation for the treatment of food allergy. The main focus of research has been directed at various forms of immunotherapy, including oral, sublingual and epicutaneous delivery routes. While oral immunotherapy (OIT) has shown the greatest promise for efficacy in terms of amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile as compared to sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), which offers the least protection but has the best safety and tolerability profile...
October 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28833704/lipopolysaccharide-suppresses-ige-mast-cell-mediated-reactions
#20
N Wang, M McKell, A Dang, A Yamani, L Waggoner, S Vanoni, T Noah, D Wu, A Kordowski, J Köhl, K Hoebe, S Divanovic, S P Hogan
BACKGROUND: Clinical and experimental analyses have identified a central role for IgE/FcεRI/mast cells in promoting IgE-mediated anaphylaxis. Recent data from human studies suggest that bacterial infections can alter susceptibility to anaphylaxis. OBJECTIVE: We examined the effect of LPS exposure on the induction of IgE-mast cell (MC) mediated reactions in mice. METHODS: C57BL/6 WT, tlr4(-/-) and IL10(-/-) mice were exposed to LPS, and serum cytokines (TNF and IL-10) were measured...
August 21, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
keyword
keyword
41626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"